Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial

or

Watchlist | Portfolio

quotes
- Price Overview
- Performance Report
charts
- Interactive Chart
- Snapshot Chart
technicals
company
analysts
- Earnings Estimates
- Analyst Ratings
financials

Mira Pharmaceuticals Inc (MIRA)

Mira Pharmaceuticals Inc (MIRA)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]

[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]

[[ session ]] by (Cboe BZX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]

[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]

[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]

News & Headlines for [[ item.sessionDateDisplayLong ]]

Charts, tickers, traders - iStock-884650780

Mira Pharmaceuticals Stock Is Soaring In November... Here's Why Barchart Impact - Wed Nov 29, 2023

Leveraging a favorable DEA classification for its synthetic analog of THC, Mira Pharmaceuticals could be on an expedited pathway toward commercialization to treat several unmet neurological m

MIRA Pharmaceuticals Shows its Prescription Pill More Palatable and Potent Than Pot PR Newswire - Mon Sep 18, 2023

/PRNewswire/ -- MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA) ("MIRA" or the "Company"), a pre-clinical-stage pharmaceutical company focused on the development and...

MIRA Pharmaceuticals and MZ Group Partner to Strengthen Investor Relations and Shareholder Communication Efforts PR Newswire - Tue Sep 5, 2023

/PRNewswire/ -- MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA) ("MIRA" or the "Company"), a pre-clinical-stage pharmaceutical company focused on the development and...

MIRA Pharmaceuticals to Participate in 6th Annual Cannabinoid-Derived Drug Development Summit PR Newswire - Thu Aug 31, 2023

/PRNewswire/ -- MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA) ("MIRA" or the "Company"), a pre-clinical-stage pharmaceutical company focused on the development and...

MIRA Pharmaceuticals to Host Virtual Roadshow Webinar on Monday, September 11, 2023 at 1:00 p.m. Eastern Time PR Newswire - Tue Aug 29, 2023

/PRNewswire/ -- MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA) ("MIRA" or the "Company"), a pre-clinical-stage pharmaceutical company focused on the development and...

MIRA Pharmaceuticals to Ring the Nasdaq Opening Bell on Wednesday, August 9, 2023 PR Newswire - Wed Aug 9, 2023

/PRNewswire/ -- MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA) ("MIRA" or the "Company"), a pre-clinical-stage pharmaceutical company focused on the development and...

MIRA Pharmaceuticals, Inc. Announces Closing of $8.9 Million Initial Public Offering PR Newswire - Mon Aug 7, 2023

/PRNewswire/ -- MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA) ("MIRA" or the "Company"), a pre-clinical-stage pharmaceutical company focused on the development and...

MIRA Pharmaceuticals, Inc. Announces Pricing of $8.9 Million Initial Public Offering and Nasdaq Listing PR Newswire - Wed Aug 2, 2023

/PRNewswire/ -- MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA) ("MIRA" or the "Company"), a pre-clinical-stage pharmaceutical company focused on the development and...

GURU Announces Closing of Subscription Receipt Financing Globe NewsWire - Wed Sep 30, 2020

Company raises $34.5 million for its Canadian and U.S. expansion in advance of its Going Public Transaction

Want to use this as
your default charts setting?

Save this setup as a Chart Templates

Switch the Market flag

for targeted data from your country of choice.

Open the menu and switch the
Market flag for targeted data from your country of choice.

Want Streaming Chart Updates?

Switch your Site Preferences
to use Interactive Charts

Need More Chart Options?

Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar